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ABSTRACT
Bloodstream infections are potentially life-threatening diseases. They can cause serious secondary
infections, such as infective endocarditis and osteomyelitis, and may result in severe sepsis. One of the
most critical determinants of survival is the induction of timely and effective antibiotic therapy. One of
the leading causes of bloodstream infections is Staphylococcus aureus, with an increasing proportion of
isolates being resistant to methicillin. Methicillin-resistant S. aureus (MRSA) is associated with greater
morbidity and mortality rates than methicillin-sensitive S. aureus (MSSA). Standard-of-care antibiotic
treatments for S. aureus bloodstream infections are limited by toxicity and ⁄ or differential efﬁcacy against
MRSA and MSSA, which makes the choice of empirical therapy difﬁcult. New management strategies
are required to address the challenges raised by S. aureus bloodstream infections and MRSA in
particular. These may include the use of techniques that allow the early identiﬁcation of complications
arising from S. aureus bacteraemia, rapid pathogen identiﬁcation to enable the administration of
appropriate antibiotic therapy, and the identiﬁcation of new drugs with novel modes of action that may
circumvent antibiotic resistance and enable effective empirical treatment of both MSSA and MRSA
infections.
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INTRODUCTION
Bacteraemia, literally deﬁned as viable bacteria in
the blood, is typically transient, but may become
persistent and develop into a serious bloodstream
infection with clinical symptoms such as fever
and chills. As a result of the combined effects of
bacterial toxins and the immune response, blood-
stream infections can result in sepsis and septic
shock, indicated by hypotension, and ﬁnally
result in multiple organ failure [1]. Bloodstream
infections may be classiﬁed as primary, when the
source of infection is unknown, or secondary,
when infection has developed subsequent to a
documented infection with the same microorgan-
ism at another site. The proportion of blood-
stream infections with an unknown source is
variable but substantial, ranging from 12% to
over 50% [2–11]. Bacteraemia is the principal
means by which bacterial infections are spread to
distant sites, and it may result in complications
arising from deep-seated secondary infections,
such as endocarditis, osteomyelitis and septic
arthritis [9,12].
STAPHYLOCOCCUS AUREUS
BACTERAEMIA (SAB) AND
BLOODSTREAM INFECTIONS
A large proportion of cases of bacteraemia are
caused by S. aureus, which is a pathogen of
particular concern because of the severity of the
infections that it can cause [13,14], its rising
incidence [15–18], the changing epidemiology of
associated infections [19] and its increasing asso-
ciation with methicillin resistance [15,20]. The
proportion of methicillin-resistant S. aureus
(MRSA) isolates from cases of bacteraemia has
been increasing in many European countries [20],
and in the UK the proportion of SAB cases
associated with MRSA peaked at 43% in 2002
[21]. The incidence of MRSA continues to vary
dramatically among countries. The European
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Antimicrobial Resistance Surveillance System
reported MRSA infection rates ranging from less
than 2% in Norway, Sweden, The Netherlands
and Denmark to greater than 40% in the UK,
Ireland, Greece, Portugal and Romania [20].
The incidence of nosocomial SAB is rising, with
reported increases of 283% in non-teaching hos-
pitals and 176% in large teaching hospitals in the
USA from 1980 to 1989 [15]. The increased use of
invasive procedures, prosthetic devices and intra-
vascular catheters [22] (e.g., those used for hae-
modialysis in patients with renal failure [23]) is
thought to be a major contributing factor. A
substantial proportion of cases of SAB have been
found to originate from organisms carried in the
patient’s own nasal mucosa [24], with up to 80%
of the population being intermittent (c. 60%) or
persistent (c. 20%) carriers [25]. SAB caused by
MRSA is associated with a longer median length
of hospital stay, higher median total treatment
cost and greater risk of mortality than bacter-
aemia due to any other bacterial pathogen [14,26],
making rapid, effective treatment a priority.
An emerging problem is the appearance of
community-acquired SAB caused by virulent
strains of MRSA [15,17,27]. Community-acquired
S. aureus infections can affect patients with few, or
without, traditional healthcare-associated risk-
factors [17,27], and community acquisition is a
risk-factor for the development of complications
[9,17,28]. The potential of community-acquired
SAB to become a healthcare issue as serious as
nosocomial infections highlights the need for
better management strategies for bloodstream
infections [29].
CURRENT MANAGEMENT
STRATEGIES
Despite growing awareness of the unique clinical
challenges posed by SAB, there is currently no
international consensus concerning its optimal
management, although various local recommen-
dations and speciﬁc guidelines for catheter-related
bloodstream infections and the management of
infective endocarditis caused by SAB have been
published [30–33].
The initial diagnosis of SAB is dependent upon
a blood culture positive for S. aureus [34]. There
exists the possibility of contamination of samples
from S. aureus colonising the skin, but even a
single positive culture from multiple sets of blood
cultures is signiﬁcant enough to warrant treat-
ment for bacteraemia [34]. Rapid initiation of
treatment is strongly recommended for suspected
SAB, and saves patients’ lives [35]. Therefore,
initial antibiotic therapy is often empirical, pro-
viding coverage for likely infecting strains on the
basis of clinical examination, patient history, local
prevalence and resistance patterns [31,34]. It is
recommended that immunocompetent patients
who show no evidence of complications should
be treated with antibiotics for 10–14 days [22,31].
For immunocompromised patients with persis-
tent bacteraemia or those showing evidence of
complications such as endocarditis, 4–6 weeks of
therapy should be considered, and this may be
further increased to 6–8 weeks in the presence of
osteomyelitis [31].
The removal of infected intravenous catheters
and hardware is recommended practice wherever
possible and is embodied in US Treatment
Guidelines from the Infectious Diseases Society
of America [31]. Culture of catheters may be
carried out when this is the suspected cause of the
bloodstream infection [31], and patients should
immediately receive antimicrobial therapy tai-
lored for the most likely infecting pathogens. The
US guidelines also explicitly recognise the role of
surgical management, recommending surgical
intervention and exploration, including draining
and excision, in cases of severe and persistent
infections where septic thrombosis is present in
peripheral veins and arteries or where the infec-
tion has spread into surrounding tissues [31].
DEVELOPING NEW MANAGEMENT
STRATEGIES FOR SAB AND
BLOODSTREAM INFECTIONS
Changes in the epidemiology of SAB, in particular
the rising prevalence of MRSA, which is associ-
ated with signiﬁcantly higher rates of morbidity
and mortality than methicillin-susceptible S. aur-
eus (MSSA) [13,14], call for the medical commu-
nity to examine the limitations of current
treatment policies and urgently address the need
for the development of new management strate-
gies.
The inability to rapidly identify and characte-
rise infecting organisms means that initial antibi-
otic therapy is often empirical [36]. This may
result in inappropriate treatment, which is
associated with extended overall duration of
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hospitalisation [35], increased risk of patient
mortality and increased overall cost of treatment
[14,37,38]—particularly for those infected with
MRSA. Standard-of-care antibiotic therapies for
MSSA infections, e.g., cephalosporins, ﬂucloxacil-
lin or nafcillin, are ineffective against MRSA, and,
conversely, agents effective against MRSA, e.g.,
vancomycin, are inferior to the standard-of-care
therapies for MSSA, as demonstrated by a higher
failure rate among MSSA bacteraemia patients
treated with vancomycin than among those
treated with nafcillin [39].
It is desirable for new antimicrobial agents to be
effective against both susceptible and resistant
pathogens, in order to allow effective early
empirical treatment prior to the delay implicit in
identiﬁcation and characterisation of the infecting
pathogen by laboratory analysis. Faster identiﬁ-
cation would allow earlier administration of
effective targeted antibiotics, thereby making
possible more rapid resolution of bacterial infec-
tions and reduced duration of hospitalisation,
which is the most costly aspect of treatment [40].
This review discusses three key targets for
future management strategies that might make a
substantial contribution towards the achievement
of these objectives, including: the early identiﬁca-
tion of complications via application of appropri-
ate tests and diagnostic criteria that can direct the
clinician rapidly to the speciﬁc treatment strate-
gies most likely to reduce patient morbidity and
the risk of mortality [9,37]; the development of
techniques and assays for the rapid identiﬁcation
of pathogens and their susceptibilities to fre-
quently used antibiotics, in order to administer
effective early therapy [41], which may allow
early discharge and ⁄ or receipt of antibiotic ther-
apy as an outpatient [40]; and the identiﬁcation of
new drugs with novel modes of action that may
circumvent antibiotic resistance [42] and enable
effective empirical treatment of both MSSA and
MRSA infections.
FUTURE STRATEGIES FOR
TREATING BLOODSTREAM
INFECTIONS
Early identiﬁcation of complications
Failure to identify SAB may lead to delayed
administration of appropriate antibiotic therapy
and an increased risk of morbidity and mortality
[43]. Early identiﬁcation of bloodstream infec-
tions, combined with the rapid initiation of
appropriate antibiotic therapy, is likely to reduce
the risk of complications such as endocarditis and
osteomyelitis. These complications are relatively
common, with reported frequencies of 11–53%
[1], but they may be difﬁcult to identify at the
time of the initial blood culture positive result [9].
In a prospective, observational study of a cohort
of patients with at least one blood culture positive
for S. aureus, the most common complications
were infective endocarditis, septic arthritis, deep-
tissue abscesses and vertebral osteomyelitis,
occurring in 12%, 7.5%, 5.7% and 3.0% of
patients, respectively [9].
Characteristics of SAB that are predictive of
complications include: infections acquired in the
community, the presence of a prosthetic device,
human immunodeﬁciency virus-positive status or
intravenous drug abuse, persistent fever at 72 h,
new cardiac murmur, positive follow-up blood
culture result, and the presence of skin lesions [9].
Fowler et al. have demonstrated that a scoring
system based on the presence of four readily
available clinical risk-factors can accurately iden-
tify complicated SAB in an individual patient
(bootstrap-corrected c-index 0.76) [9]. Patient
scores were the sum of points allocated for
speciﬁc risk-factors: one point each was given
for the presence of community-acquired SAB,
skin examination ﬁndings suggesting the pres-
ence of acute systemic infection and persistent
fever at 72 h; two points were given for a positive
follow-up blood culture result at 48–96 h, this
being the strongest predictor of complicated SAB
(OR, 5.58; 95% CI, 1.96–4.87) [9]. The predicted
rate of complications was 16% in the absence of
any of these risk-factors and rose progressively
with increasing scores—to greater than 90% for
scores of 5 (Fig. 1) [9].
Decreased time to pathogen identiﬁcation
Identiﬁcation of bacteria in patient isolates and
antibiotic susceptibility testing can take up to
3 days—time enough for a substantial deteriora-
tion in a patient’s clinical condition. There is thus
interest in developing and reﬁning laboratory
techniques that can accelerate these processes.
PCR is the most sensitive of the existing rapid
methods for detecting pathogens in clinical spec-
imens [44]. However, this technique has several
28 Clinical Microbiology and Infection, Volume 14, Supplement 2, March 2008
 2008 The Author
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 2), 26–34
limitations, including the susceptibility of PCR to
inhibitors and contamination, and variability due
to differences in experimental conditions [44]. The
sensitivity of the PCR method is dependent on the
target genes, the primer sequences, the DNA
extraction procedures and PCR product detection
methods, as well as on the quality and concen-
tration of DNA available from different types of
clinical specimen, e.g., blood, tissue or sputum
[44]. The high sensitivity of PCR implies that it
can successfully reveal pathogens that are difﬁ-
cult to culture [44]. However, the signiﬁcance of a
positive PCR result requires considered interpre-
tation, because bacterial DNA can persist after an
active infection has resolved; for example, bacte-
rial DNA has been detected in heart valve
samples from patients undergoing valve replace-
ment following a previous episode of infective
endocarditis [45,46]. Such cases may indicate
either the recurrence of bacterial infection, treat-
ment failure, or the persistence of bacterial debris
without any evidence of infection, presumably as
a result of bacterial cell death and incomplete
clearance [46,47].
New methods of pathogen identiﬁcation based
on the PCR technique are now being developed
and marketed. An innovative real-time PCR test
has been designed to detect and identify the 25
most important bacterial and fungal species caus-
ing bloodstream infections in less than 6 h. The
test uses 3 mL of whole blood samples, eliminat-
ing the need for prior incubation or culture steps
and dramatically decreasing the time to pathogen
identiﬁcation. However, this test does not distin-
guish between MRSA and MSSA, and therefore
would not eliminate the need for empirical
treatment of S. aureus bloodstream infections.
Also, special reagents and plastic-ware are
required, which may impact the cost of testing
(http://www.roche.com/home/products/prod_
diag_lc-septif.htm).
A PCR-based hybridisation assay, developed as
an alternative method of pathogen identiﬁcation
in the form of a dipstick test, has a time-to-result
of 2 h 20 min and reliably reveals the presence of
MRSA—even in mixed cultures [48]. This test has
a diagnostic sensitivity of 100%, a positive pre-
dictive value of 96% and a negative predictive
value of 100%; however, it does not identify
MSSA and coagulase-negative staphylococci,
which both give a negative test result. Therefore,
it appears reasonable to use this test subsequent
to the identiﬁcation of staphylococci by a different
test.
Identiﬁcation of new drugs
Current antibiotics vary in terms of their efﬁcacy
against susceptible and resistant pathogens, their
safety and tolerability, and their ability to be
combined with other antibiotics and concomitant
medications. Oxacillin–ﬂucloxacillin and cephalo-
sporins are highly effective against MSSA, but
have low efﬁcacy against MRSA [49]. Conversely,
vancomycin is the standard therapy for MRSA
[50], but is less effective than b-lactams against
MSSA [51] and has signiﬁcant drawbacks, includ-
ing inconvenient administration, poor tolerability
[52] and emerging resistance issues [53]. True
resistance to vancomycin is still restricted to a
relatively small proportion of Gram-positive
microorganisms [54–59]. However, there are addi-
tional concerns, such as an observed tolerance to
vancomycin in 15% of wild-type MRSA isolates
[60], and the increasing MICs in susceptible
strains, signiﬁcantly affecting clinical success in
patients with MRSA [61]. Teicoplanin—like
vancomycin, a glycopeptide antibiotic that is
active against MRSA—is generally well-tolerated,
but requires a complicated dosing schedule and
has similar resistance issues to those of vancomy-
cin [62].
The development of new antibiotics that are
effective against both MSSA and MRSA is neces-
sary for the future management of bloodstream
infections in an environment where MRSA is
increasing in prevalence (Fig. 2). Studies suggest
that many patients subsequently found to have
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Fig. 1. Association between Staphylococcus aureus bactera-
emia (SAB) score and probability of complications. 1 point
each for community-acquired SAB, skin examination
ﬁndings suggesting the presence of acute systemic infec-
tion, and persistent fever at 72 h; 2 points for positive
follow-up blood culture result at 48–96 h.
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infections caused by MRSA were initially treated
with drugs that are not effective against MRSA: in
one such study, 42 (40.8%) MRSA-infected
patients had not received appropriate treatment
by 44.75 h, as compared with six (9.3%) MSSA
patients [35]. Inappropriate initial treatment
resulted in the delayed administration of appro-
priate therapy, and this was determined to be an
independent predictor of mortality (33.2% vs.
19.3% in the early treatment group, p ¼ 0.05) [35].
With respect to the currently available drugs,
linezolid shows efﬁcacy against both MSSA and
MRSA. Moreover, it has the advantage of both
oral and intravenous administration options [63].
Unfortunately, serious safety and tolerability
issues have recently been raised [63,64], including
the ﬁnding of an increased rate of mortality in
patients with bloodstream infections caused by
mixed Gram-positive and Gram-negative patho-
gens, or by Gram-negative pathogens alone
[17,65].
Several antibiotics have recently received, or
are expected to receive, European approval for
the treatment of Gram-positive infections, includ-
ing bloodstream infections, in 2007 and 2008
(Table 1).
Daptomycin is a new antibiotic, indicated for
the treatment of complicated skin and soft-tissue
infections (cSSTIs) and of SAB, including that
associated with right-sided infective endocarditis
(RIE), in the USA [66,67]. Marketing authorisation
has recently been extended in Europe to include
the indications of RIE caused by S. aureus and
SAB when associated with a cSSTI or RIE [67].
0 10 20 30 40 50 60 70 80
UK
SK
RO
PT
NL
HU
DK
DE
CZ
BE
Co
un
try
MRSA, %
1999
2000
2001
2002
2003
2004
2005
Fig. 2. The percentage of Staphylococcus aureus isolates
with methicillin resistance in those European countries in
the European Antimicrobial Resistance Survellance System
database that showed signiﬁcant increases from 1999 to
2005. BE, Belgium; CZ, Czech Republic; DE, Germany; DK,
Denmark; HU, Hungary; NL, The Netherlands; PT, Portu-
gal; RO, Romania; SK, Slovakia; UK, United Kingdom
(European Antimicrobial Resistance Survellance System
database, available at http://www.rivm.nl/earss/data-
base/).
Table 1. Recently approved and investigational antibiotics for treatment of Gram-positive infections
Approval date Class
Indications or
potential
indications
Dose or
anticipated dose Action References
Recently approved for marketing
Daptomycin US: 2003, 2006
EU: 2006, 2007
Cyclic lipopeptides cSSTI
SAB ⁄RIE
4 mg ⁄ kg or 6 mg ⁄kg
IV once-daily
Bactericidal 66,67
Tigecycline US: 2005
EU: 2006
Glycylcycline cSSTI
cIAI
100 mg then 50 mg
IV twice-daily
Bacteriostatic 81,82
Projected approval
Dalbavancin US: 2008
EU: 2008
Lipoglycopeptide uSSTI
cSSTI
CR-BSI
1 g, then 500 mg
IV once-weekly
Bactericidal 76
Telavancin 2008 Lipoglycopeptide cSSTI
(SAB ⁄ IE)
10 mg ⁄ kg IV
once-daily
Bactericidal 78
Ceftobiprole US: 2008
EU: 2009
Cephalosporin cSSTI
CR-BSI
(HAP)
500 mg IV
three-times-daily
Bactericidal 83,
Strauss
et al. (2007)a
cIAI, complicated intra-abdominal infection; CR-BSI, catheter-related bloodstream infection; cSSTI, complicated skin and
soft-tissue infection; HAP, hospital-acquired pneumonia; IE, infective endocarditis; IV, intravenous; SAB ⁄RIE, Staphylo-
coccus aureus bacteraemia ⁄ right-sided infective endocarditis; uSSTI, uncomplicated skin and soft-tissue infection.
aStrauss RS, Bagchi P, Noel GJ. Interscience Conference on Antimicrobial Agents and Chemotherapy, 2007; Poster L-1145.
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Daptomycin has a novel mechanism of action,
and no signiﬁcant cross-resistance with other
classes is expected. Cross-resistance with vanco-
mycin has been observed in vitro in a small
number of glycopeptide-intermediate S. aureus
isolates [68], which themselves represent a pop-
ulation of only <0.3% of S. aureus [69]. However,
the signiﬁcance of these in-vitro ﬁndings is
unknown at this time. Daptomycin has demon-
strated sustained activity against clinical isolates
of S. aureus, and no MIC shift was observed from
2002 through 2005 [70]. The advantages of dap-
tomycin over currently used antibiotics include its
activity against a variety of Gram-positive bacte-
ria (including MRSA) [51,71], in both growing and
stationary phases [72], and its bactericidal action
with negligible cell lysis, which reduces the risk of
severe inﬂammatory response syndrome [73].
Once-daily dosing also makes parenteral admin-
istration to outpatients feasible.
A phase III trial compared daptomycin with
vancomyin or semi-synthetic penicillins, both
with adjuvant gentamicin, in patients with SAB
and ⁄ or endocarditis [74]. Overall clinical success
rates at test of cure were similar in the daptomy-
cin and comparator antibiotic groups (44.2% with
daptomycin vs. 41.7% with comparator antibiot-
ics) [74], and, although there was a trend for
daptomycin to be superior to the comparator
against MRSA (44.4% vs. 31.8%, respectively),
daptomycin was non-inferior to semi-synthetic
penicillins with gentamicin against MSSA (44.6%
vs. 48.6%, respectively) [74]. The latter ﬁnding
may be even more important, because it would
allow the use of the drug in empirical treatment of
all suspected S. aureus infections. Clinical success
rates were relatively low, due to the stringency of
the cure rate criteria; the deﬁnitions of treatment
failure included failure to obtain a blood culture,
and receipt of potentially effective non-study
antibiotics, as well as clinical and microbiological
failure, or discontinuation due to a serious
adverse effect [74].
Daptomycin was found to have good levels of
safety and tolerability, showing a pattern and
incidence of adverse effects similar to those of
comparator antibiotics, with the exception of
renal impairment, the occurrence of which was
signiﬁcantly greater in patients treated with com-
parator agents [74]. Creatine phosphokinase lev-
els were elevated in 9.2% of patients treated with
daptomycin, as compared with 1.7% of patients
in the comparator antibiotic groups; however,
musculo-skeletal effects were observed in fewer
daptomycin-treated patients (29.2%) than com-
parator-treated patients (36.2%) [74].
Tigecycline is a broad-spectrum, glycylcycline
antibiotic covering both Gram-positive and Gram-
negative pathogens, but its action is bacteriostatic,
which is disadvantageous in the treatment of
deep-seated infections [75]. It has approval for the
treatment of cSSTIs and intra-abdominal infec-
tions, and, although studies have shown promis-
ing efﬁcacy against bloodstream infections, no
speciﬁc clinical trials have been completed to date
for this indication.
Three investigational antibiotics effective
against Gram-positive pathogens are expected to
receive approval over the next few years.
Dalbavancin is a lipoglycopeptide antibiotic
from the same class as vancomycin, with bacteri-
cidal activity against Gram-positive pathogens,
including MRSA, and is appropriate for once-
weekly intravenous administration [76]. It is
expected to acquire approval for treatment of
cSSTIs in 2008 in both the USA and the EU, and has
shown promising efﬁcacy against catheter-related
bloodstream infections caused by staphylococci,
including MRSA, in a phase II clinical trial [77].
Telavancin is also from the lipoglycopeptide
class, with bactericidal activity against Gram-
positive pathogens, including MRSA, and is
appropriate for once-daily administration. It has
a dual mechanism of action, involving both
inhibition of cell-wall synthesis and depolarisa-
tion of the bacterial cell membrane [78]. Telavan-
cin is expected to receive approval for the
treatment of cSSTIs in 2008, and, although the
drug has shown promising preclinical efﬁcacy
against SAB models, there are no published
clinical trial data for SAB to date.
Ceftobiprole is a late-generation cephalospo-
rin, with bactericidal activity against a wide
variety of Gram-positive bacteria, including
MRSA [79]. The activity of ceftobiprole against
MRSA in vitro is favourable, with MICs similar
to those of daptomycin (MIC90 1 mg ⁄L) [80].
However, administration is inconvenient, with
1–2-h infusions required two or three times
daily, and the drug is associated with a high
incidence of adverse events. EU approval for
treatment of the indications of hospital-acquired
and nosocomial pneumonia and cSSTIs is
expected in 2009.
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CONCLUSION
Current management strategies for the treatment
of bloodstream infections are becoming increas-
ingly limited because of the rising incidence of
resistant pathogens such as MRSA. This high-
lights the need for new management strategies,
such as techniques to aid early diagnosis, rapid
identiﬁcation of infecting pathogens and the
development of new antibiotics that are effective
against both MSSA and MRSA. Addressing these
needs will allow effective and timely treatment of
bloodstream infections, particularly those caused
by MRSA, which is crucial for the prevention of
complications and to reduce the risk of patient
morbidity and mortality.
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